Literature DB >> 21741971

Regulation of homeostasis and oncogenesis in the intestinal epithelium by Ras.

Sergia Velho1, Kevin M Haigis.   

Abstract

Much of our current state of knowledge pertaining to the mechanisms controlling intestinal epithelial homeostasis derives from epidemiological, molecular genetic, cell biological, and biochemical studies of signaling pathways that are dysregulated during the process of colorectal tumorigenesis. Activating mutations in members of the RAS oncoprotein family play an important role in the progression of colorectal cancer (CRC) and, by extension, intestinal epithelial homeostasis. Mutations in K-RAS account for 90% of the RAS mutations found in CRC. As such, the study of RAS protein function in the intestinal epithelium is largely encompassed by the study of K-RAS function in CRC. In this review, we summarize the data available from genetically defined in vitro and in vivo models of CRC that aim to characterize the oncogenic properties of mutationally activated K-RAS. These studies paint a complex picture of a multi-functional oncoprotein that engages an array of downstream signaling pathways to influence cellular behaviors that are both pro- and anti-tumorigenic. While the complexity of K-RAS biology has thus far prevented a comprehensive understanding of its oncogenic properties, the work to date lays a foundation for the development of new therapeutic strategies to treat K-RAS mutant CRC. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21741971      PMCID: PMC3192920          DOI: 10.1016/j.yexcr.2011.06.002

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  60 in total

1.  Recurrent KRAS codon 146 mutations in human colorectal cancer.

Authors:  Sarah Edkins; Sarah O'Meara; Adrian Parker; Claire Stevens; Marcelo Reis; Siân Jones; Chris Greenman; Helen Davies; Gillian Dalgliesh; Simon Forbes; Chris Hunter; Raffaella Smith; Philip Stephens; Peter Goldstraw; Andrew Nicholson; Tsun Leung Chan; Victor E Velculescu; Siu Tsan Yuen; Suet Yi Leung; Michael R Stratton; P Andrew Futreal
Journal:  Cancer Biol Ther       Date:  2006-08-01       Impact factor: 4.742

2.  Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells.

Authors:  Claire B Pollock; Senji Shirasawa; Takehiko Sasazuki; Walter Kolch; Amardeep S Dhillon
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

3.  APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.

Authors:  Klaus-Peter Janssen; Paola Alberici; Hafida Fsihi; Claudia Gaspar; Cor Breukel; Patrick Franken; Christophe Rosty; Miguel Abal; Fatima El Marjou; Ron Smits; Daniel Louvard; Riccardo Fodde; Sylvie Robine
Journal:  Gastroenterology       Date:  2006-08-16       Impact factor: 22.682

Review 4.  Transforming growth factor-beta in cancer and metastasis.

Authors:  Sonia B Jakowlew
Journal:  Cancer Metastasis Rev       Date:  2006-09       Impact factor: 9.264

5.  Oncogenic Ras increases sensitivity of colon cancer cells to 5-FU-induced apoptosis.

Authors:  Lidija Klampfer; Laurie-Anne Swaby; Jie Huang; Takehiko Sasazuki; Senji Shirasawa; Leonard Augenlicht
Journal:  Oncogene       Date:  2005-06-02       Impact factor: 9.867

6.  Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK-3beta.

Authors:  Jingnan Li; Yusuke Mizukami; Xiaobo Zhang; Won-Seok Jo; Daniel C Chung
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

7.  Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells.

Authors:  K Rosen; J Rak; T Leung; N M Dean; R S Kerbel; J Filmus
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

8.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

9.  Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

Authors:  John Rinehart; Alex A Adjei; Patricia M Lorusso; David Waterhouse; J Randolph Hecht; Ronald B Natale; Oday Hamid; Mary Varterasian; Peggy Asbury; Eric P Kaldjian; Stephen Gulyas; David Y Mitchell; Roman Herrera; Judith S Sebolt-Leopold; Mark B Meyer
Journal:  J Clin Oncol       Date:  2004-10-13       Impact factor: 44.544

10.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo.

Authors:  Owen J Sansom; Valerie Meniel; Julie A Wilkins; Alicia M Cole; Karin A Oien; Victoria Marsh; Thomas J Jamieson; Carmen Guerra; Gabrielle H Ashton; Mariano Barbacid; Alan R Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-07       Impact factor: 11.205

View more
  7 in total

1.  RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.

Authors:  Oghenekevwe M Gbenedio; Caroline Bonnans; Delphine Grun; Chih-Yang Wang; Ace J Hatch; Michelle R Mahoney; David Barras; Mary Matli; Yi Miao; K Christopher Garcia; Sabine Tejpar; Mauro Delorenzi; Alan P Venook; Andrew B Nixon; Robert S Warren; Jeroen P Roose; Philippe Depeille
Journal:  JCI Insight       Date:  2019-06-25

2.  Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS.

Authors:  Michelle Demory Beckler; James N Higginbotham; Jeffrey L Franklin; Amy-Joan Ham; Patrick J Halvey; Imade E Imasuen; Corbin Whitwell; Ming Li; Daniel C Liebler; Robert J Coffey
Journal:  Mol Cell Proteomics       Date:  2012-11-15       Impact factor: 5.911

Review 3.  Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans.

Authors:  Chad M Thompson; Deborah M Proctor; Mina Suh; Laurie C Haws; Christopher R Kirman; Mark A Harris
Journal:  Crit Rev Toxicol       Date:  2013-03       Impact factor: 5.635

4.  Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation.

Authors:  Douglas K Brubaker; Joao A Paulo; Shikha Sheth; Emily J Poulin; Olesja Popow; Brian A Joughin; Samantha Dale Strasser; Alina Starchenko; Steven P Gygi; Douglas A Lauffenburger; Kevin M Haigis
Journal:  Cell Syst       Date:  2019-09-11       Impact factor: 10.304

Review 5.  The crossroads between cancer stem cells and aging.

Authors:  Sara Santos Franco; Hadas Raveh-Amit; Julianna Kobolák; Mohammed H Alqahtani; Ali Mobasheri; András Dinnyes
Journal:  BMC Cancer       Date:  2015-01-15       Impact factor: 4.430

6.  Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes.

Authors:  Yongchao Dou; Diana J Cha; Jeffrey L Franklin; James N Higginbotham; Dennis K Jeppesen; Alissa M Weaver; Nripesh Prasad; Shawn Levy; Robert J Coffey; James G Patton; Bing Zhang
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

7.  Modulation of Fibroblast Phenotype by Colorectal Cancer Cell-Secreted Factors Is Mostly Independent of Oncogenic KRAS.

Authors:  Patrícia Dias Carvalho; Susana Mendonça; Flávia Martins; Maria José Oliveira; Sérgia Velho
Journal:  Cells       Date:  2022-08-11       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.